The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00065325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Study identification
- NCT ID
- NCT00065325
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 694 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 32 Years to 91 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2003 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Sep 2014 (Actual)
- Last update posted
- Feb 24, 2015
2003 – 2014
United States locations
- U.S. sites
- 51
- U.S. states
- 24
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Arcadia | California | — | — |
| Research Site | Fountain Valley | California | — | — |
| Research Site | Laverne | California | — | — |
| Research Site | Long Beach | California | — | — |
| Research Site | Santa Rosa | California | — | — |
| Research Site | Torrington | Connecticut | — | — |
| Research Site | Washington D.C. | District of Columbia | — | — |
| Research Site | Boca Raton | Florida | — | — |
| Research Site | Gainesville | Florida | — | — |
| Research Site | Jacksonville | Florida | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | New Port Richey | Florida | — | — |
| Research Site | Pensacola | Florida | — | — |
| Research Site | Athens | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Harvey | Illinois | — | — |
| Research Site | Springfield | Illinois | — | — |
| Research Site | Iowa City | Iowa | — | — |
| Research Site | Overland Park | Kansas | — | — |
| Research Site | Baton Rouge | Louisiana | — | — |
| Research Site | Metairie | Louisiana | — | — |
| Research Site | New Orleans | Louisiana | — | — |
| Research Site | Shreveport | Louisiana | — | — |
| Research Site | Bangor | Maine | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Frederick | Maryland | — | — |
| Research Site | Kalamazoo | Michigan | — | — |
| Research Site | Royal Oak | Michigan | — | — |
| Research Site | Saint Joseph | Michigan | — | — |
| Research Site | Hooksett | New Hampshire | — | — |
| Research Site | Livingston | New Jersey | — | — |
| Research Site | Voorhees Township | New Jersey | — | — |
| Research Site | Albuquerque | New Mexico | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Canton | Ohio | — | — |
| Research Site | Hershey | Pennsylvania | — | — |
| Research Site | Lancaster | Pennsylvania | — | — |
| Research Site | Langhorne | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Providence | Rhode Island | — | — |
| Research Site | Columbia | South Carolina | — | — |
| Research Site | Greenville | South Carolina | — | — |
| Research Site | Spartenburg | South Carolina | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Burlington | Vermont | — | — |
| Research Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00065325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2015 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00065325 live on ClinicalTrials.gov.